[go: up one dir, main page]

AR094872A1 - Anticuerpos anti-tnf-anti-il-17 biespecíficos - Google Patents

Anticuerpos anti-tnf-anti-il-17 biespecíficos

Info

Publication number
AR094872A1
AR094872A1 ARP140100576A ARP140100576A AR094872A1 AR 094872 A1 AR094872 A1 AR 094872A1 AR P140100576 A ARP140100576 A AR P140100576A AR P140100576 A ARP140100576 A AR P140100576A AR 094872 A1 AR094872 A1 AR 094872A1
Authority
AR
Argentina
Prior art keywords
antibodies
biespectific
tnf
bispecific antibodies
tnfa
Prior art date
Application number
ARP140100576A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR094872A1 publication Critical patent/AR094872A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan anticuerpos biespecíficos que enlazan específicamente tanto el Factor de Necrosis Tumoral a (TNFa) e Interleucina-17 (IL-17). Los anticuerpos biespecíficos son útiles para tratar varias enfermedades autoinmunes, incluyendo Artritis Reumatoide (RA), Artritis Psoriática (PA), y Espondilitis Anquilosante (AS). Molécula de ADN, célula, proceso para producir un anticuerpo, composición farmacéutica.
ARP140100576A 2013-03-08 2014-02-24 Anticuerpos anti-tnf-anti-il-17 biespecíficos AR094872A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361774909P 2013-03-08 2013-03-08

Publications (1)

Publication Number Publication Date
AR094872A1 true AR094872A1 (es) 2015-09-02

Family

ID=50343854

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100576A AR094872A1 (es) 2013-03-08 2014-02-24 Anticuerpos anti-tnf-anti-il-17 biespecíficos

Country Status (16)

Country Link
US (1) US9416182B2 (es)
EP (1) EP2964674B1 (es)
JP (1) JP6152433B2 (es)
KR (1) KR20150113199A (es)
CN (1) CN105283467B (es)
AP (1) AP2015008709A0 (es)
AR (1) AR094872A1 (es)
AU (1) AU2014226093A1 (es)
BR (1) BR112015018203A2 (es)
CA (1) CA2896888C (es)
EA (1) EA201591478A1 (es)
ES (1) ES2654681T3 (es)
MX (1) MX2015011957A (es)
TW (1) TW201444867A (es)
WO (1) WO2014137961A1 (es)
ZA (1) ZA201506568B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628846B (zh) * 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2015258859B2 (en) 2014-05-15 2020-07-23 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
US20160244520A1 (en) * 2015-01-24 2016-08-25 Abbvie Inc. Compositions and methods for treating psoriatic arthritis
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
WO2017113181A1 (zh) * 2015-12-30 2017-07-06 深圳先进技术研究院 IgG杂合型抗TNFα和IL-17A双特异性抗体
US20170218092A1 (en) * 2016-01-28 2017-08-03 Janssen Biotech, Inc. Bispecific Anti-TNF-Alpha/IL17A Antibodies and Anti-TNF-Alpha Antibodies and Methods of Their Use
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
US11279935B2 (en) * 2016-07-08 2022-03-22 Tak-Circulator Co, Ltd Method for screening prophylactic or therapeutic agents for diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5
CN107857818A (zh) * 2017-08-07 2018-03-30 上海科新生物技术股份有限公司 一种针对IL‑17和TNF‑α的双特异性融合蛋白
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules
KR102722731B1 (ko) * 2017-12-19 2024-10-25 젠코어 인코포레이티드 조작된 il-2 fc 융합 단백질
AR117192A1 (es) 2018-11-05 2021-07-21 Beijing Hanmi Pharmaceutical Co Ltd ANTICUERPO BIESPECÍFICO HETERODIMÉRICO SIMILAR EN ESTRUCTURA AL ANTICUERPO NATURAL ANTI-TNFa / ANTI-IL-17A, Y MÉTODO PARA SU PREPARACIÓN
IL320091A (en) 2019-01-31 2025-06-01 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
KR102323342B1 (ko) 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
WO2022072291A1 (en) * 2020-09-30 2022-04-07 Amgen Inc. Cation exchange chromatography process
CN117529506A (zh) * 2021-06-11 2024-02-06 海南先声药业有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
CN114380917B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 针对IL-17A和TNFα的双特异性单域抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (en) * 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
ES2672221T3 (es) * 2005-12-13 2018-06-13 Eli Lilly And Company Anticuerpos anti IL-17
KR101616758B1 (ko) * 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
KR101579771B1 (ko) * 2009-03-05 2015-12-28 애브비 인코포레이티드 Ｉｌ-17 결합 단백질
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos

Also Published As

Publication number Publication date
AU2014226093A1 (en) 2015-07-23
EP2964674B1 (en) 2017-11-08
CA2896888A1 (en) 2014-09-12
TW201444867A (zh) 2014-12-01
EP2964674A1 (en) 2016-01-13
US20140255406A1 (en) 2014-09-11
JP6152433B2 (ja) 2017-06-28
CA2896888C (en) 2017-11-21
BR112015018203A2 (pt) 2017-08-22
JP2016510743A (ja) 2016-04-11
MX2015011957A (es) 2016-04-07
CN105283467B (zh) 2019-04-02
WO2014137961A1 (en) 2014-09-12
EA201591478A1 (ru) 2016-03-31
ZA201506568B (en) 2017-11-29
ES2654681T3 (es) 2018-02-14
AP2015008709A0 (en) 2015-09-30
KR20150113199A (ko) 2015-10-07
US9416182B2 (en) 2016-08-16
CN105283467A (zh) 2016-01-27

Similar Documents

Publication Publication Date Title
AR094872A1 (es) Anticuerpos anti-tnf-anti-il-17 biespecíficos
CL2018000502A1 (es) Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer.
CY1121802T1 (el) Μεθοδοι αγωγης της αγκυλοποιητικης σπονδυλιτιδας με τη χρηση αντισωματων anti-il-17
AR094896A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CR20180162A (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
AR090626A1 (es) Anticuerpos anti-baff-anti-il-17 biespecificos
AR109771A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
MX2016006529A (es) Anticuerpos dobles especificos.
PH12015502819A1 (en) Anti-pd-1 antibody and use thereof
EA201300819A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
EA201492101A1 (ru) Антитела против fcrn
BR112018014585A2 (pt) receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
CL2017000711A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos.
EA201591814A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ Fc
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
EA201201435A1 (ru) ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
MX384418B (es) Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
MX380358B (es) Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer.
EA201690992A1 (ru) Антитела, специфичные к fcrn
ECSP14017562A (es) Formulación de anticuerpo il-17
UY33997A (es) Moléculas de unión biespecíficas que se unen a dii4 y ang2

Legal Events

Date Code Title Description
FB Suspension of granting procedure